Focus on musculoskeletal health in women with bleeding disorders

Alison Dougall; Laurent Frenzel

doi:10.2478/jhp-2022-0017

Abstract

Abstract

Maintaining good musculoskeletal health, including good oral health, is as important for women with bleeding disorders (WBD) as it is for men. Many people with bleeding disorders ignore bleeding from their gums, believing it to be part of their condition. However, it may be a sign of periodontal disease, which left untreated can lead to accelerated tooth loss and infection, adversely affecting overall health. A good diet and access to good dental care from childhood are important to maintaining good oral health in WBD. Joint bleeding and degeneration are not limited to people with more severe forms of haemophilia; joint-related diagnoses have been shown to be twice as common among haemophilia carriers and women with mild haemophilia than in the general population. Women with type 3 von Willebrand disease experience comparable joint outcomes to younger intensively treated patients with severe haemophilia. Neither gum nor joint bleeds should ever be considered normal, as both can be treated to avoid progressive disease. Dental and joint specialists and physiotherapists should work closely with haemophilia teams to ensure optimal care for long-term preservation of musculoskeletal health.

Article

View Full Article

References

1. Chapple ILC, Genco R et al. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontology 2013; 40 (suppl 14): 106–112. doi: https://doi.org/10.1902/jop.2013.1340011.
2. Epping L, Miesbach W, Nickles K, Eickholz P. Is gingival bleeding a symptom of type 2 and 3 von Willebrand disease? PLoS One 2018; 13(1): e0191291. doi: https://doi.org/10.1371/journal/pone.0191291.
3. Brewer A, Correa ME, on behalf of the World Federation of Hemophilia Dental Committee. Guidelines for dental treatment of patients with inherited bleeding disorders. Treatment of Haemophilia, no. 40, May 2006. Available from https://www1.wfh.org/publication/files/pdf-1190.pdf (accessed 1 September 2022).
4. Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5(1): 301–325. doi: https://doi.org/10.1182/bloodadvances.2020003264.
5. Poveda Roda R, Bagan JV, Díaz Fernández, et al. Review of temporomandibular joint pathology. Part I: classification, epidemiology and risk factors. Med Oral Patol Oral Cir Bucal 2007; 12(4): E292–8. Available from http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1698-69462007000400006&lng=es&nrm=iso (accessed 26 September 2022).
6. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002; 65(2): 615–621. Available from https://www.aafp.org/pubs/afp/issues/2002/0215/p615.html (accessed 26 September 2022).
7. Dahiya P, Kamal R, Kumar M, Gupta R, Chaudhary K. Burning mouth syndrome and menopause. Int J Prev Med 2013; 4(1): 15–20.
8. Ślebioda Z, Szponar E. Burning mouth syndrome – a common dental problem in perimenopausal women. Prz Menopauzalny 2014; 13 (3): 198–202. doi: https://doi.org/10.5114/pm.2014.43825.
9. Osooli M, Donfield SM, Carlsson KS et al. Joint comorbidities among Swedish carriers of haemophilia: A register-based cohort study over 22 years. Haemophilia 2019; 25(5): 845–850. doi: https://doi.org/10.1111/hae.13831.
10. van Galen KPM, Timmer M, de Kleijn P, et al. Long-term outcome after joint bleeds in von Willebrand disease compared to haemophilia A: a post hoc analysis. Thromb Haemost 2018; 118(10): 1690–1700. doi: https://doi.org/10.1055/s-0038-1670704.
11. Négrier C, Mahlangu J, Lehle M, et al. Emicizumab prophylaxis in persons with mild or moderate hemophilia A: Results from the interim analysis of the HAVEN 6 study. Blood 2021; 138(1): 343. doi: https://doi.org/10.1182/blood-2021-146009.
12. Hermans C, Négrier C, Lehle M, et al. Emicizumab prophylaxis for the treatment of people with moderate or mild haemophilia A without factor VIII inhibitors: Results from the primary analysis of the HAVEN 6 study [abstract]. ISTH 2022 Congress. Available from https://abstracts.isth.org/abstract/emicizumab-prophylaxis-for-the-treatment-of-people-with-moderate-or-mild-hemophilia-a-without-factor-viii-inhibitors-results-from-the-primary-analysis-of-the-haven-6-study/ (accessed 26 September 2022).
13. National Library of Medicine (US). Emicizumab for severe von Willebrand disease (VWD) and VWD/haemophilia A (BCDI-XII). 15 August 2022-. Identifier: NCT05500807. Available from https://clinicaltrials.gov/ct2/show/NCT05500807?term=Hemlibra&draw=2&rank=5 (accessed 26 September 2022).
14. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl 6): 1–158. doi: https://doi.org/10.1111/14046.
15. de Kleijn P, Duport G, Jansone K, et al; European Haemophilia Consortium and EAHAD Physiotherapy Committee. European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients. Haemophilia 2022 May 4. doi: https://doi.org/10.1111/hae.14566. Online ahead of print.
16. Citla-Sridhar D, Sidonio RF, Ahuja SP. Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis. Haemophilia 2022; 28(4): 671–678. doi: https://doi.org/10.1111/hae.14565.

PDF Download

Download PDF

Open in full-page viewer

Authors

Alison Dougall

Trinity College Dublin, Ireland
Laurent Frenzel

laurent.frenzel@aphp.fr

Hôpital universitaire Necker-Enfants maladies, Paris, France .